Abstract
Progranulin (PGRN) is a multi-functional protein which acts to promote neuronal cell growth and to reduce inflammation in the brain. Granulin (GRN) mutations were first identified in frontotemporal dementia patients with ubiquitin-positive, tau-negative brain inclusions. However, GRN mutations and GRN polymorphisms (rs5848) have been found in neurodegenerative diseases other than FTD, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), corticobasal syndrome (CBS), and amyotrophic lateral sclerosis (ALS). Recent studies showed that phosphorylated TDP-43, tau and α-synuclein accumulation was present in the brains of patients with a GRN mutation. These results suggested that GRN mutations might cause multiple proteinopathies of which the mechanisms remain unknown.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW (2007) Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol 113:245–252. https://doi.org/10.1007/s00401-006-0183-4
Antonell A et al (2012) Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer’s disease: detection of GRN mutations in a Spanish cohort. J Alzheimers Dis 31:581–591. https://doi.org/10.3233/JAD-2012-112120
Baker M et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919. https://doi.org/10.1038/nature05016
Benussi L, Binetti G, Sina E, Gigola L, Bettecken T, Meitinger T, Ghidoni R (2008) A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol Aging 29:427–435. https://doi.org/10.1016/j.neurobiolaging.2006.10.028
Benussi L, Ghidoni R, Pegoiani E, Moretti DV, Zanetti O, Binetti G (2009) Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiol Dis 33:379–385. https://doi.org/10.1016/j.nbd.2008.11.008
Boeve BF et al (2006) Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain J Neurol 129:3103–3114. https://doi.org/10.1093/brain/awl268
Brouwers N et al (2007) Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol 64:1436–1446. https://doi.org/10.1001/archneur.64.10.1436
Brouwers N et al (2008) Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71:656–664. https://doi.org/10.1212/01.wnl.0000319688.89790.7a
Carecchio M et al (2009) Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic mild cognitive impairment converted to Alzheimer’s disease. J Neurol Sci 287:291–293. https://doi.org/10.1016/j.jns.2009.07.011
Carecchio M et al (2014) Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism. J Alzheimers Dis 38:747–752. https://doi.org/10.3233/JAD-131151
Chang KH et al (2013) Association between GRN rs5848 polymorphism and Parkinson’s disease in Taiwanese population. PLoS One 8:e54448. https://doi.org/10.1371/journal.pone.0054448
Chang KH et al (2018) Genetic and functional characters of GRN p.T487I mutation in Taiwanese patients with atypical Parkinsonian disorders. Parkinsonism Relat Disord 51:61–66. https://doi.org/10.1016/j.parkreldis.2018.02.045
Coppola C et al (2012) A progranulin mutation associated with cortico-basal syndrome in an Italian family expressing different phenotypes of fronto-temporal lobar degeneration. Neurol Sci 33:93–97. https://doi.org/10.1007/s10072-011-0655-8
Cortini F et al (2008) Novel exon 1 progranulin gene variant in Alzheimer’s disease. Eur J Neurol 15:1111–1117. https://doi.org/10.1111/j.1468-1331.2008.02266.x
Cruts M et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924. https://doi.org/10.1038/nature05017
Daniel R, Daniels E, He Z, Bateman A (2003) Progranulin (acrogranin/PC cell-derived growth factor/granulin-epithelin precursor) is expressed in the placenta, epidermis, microvasculature, and brain during murine development. Dev Dyn 227:593–599. https://doi.org/10.1002/dvdy.10341
Dickson DW et al (1994) Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. Acta Neuropathol 88:212–221
Dickson DW, Baker M, Rademakers R (2010) Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegener Dis 7:170–174. https://doi.org/10.1159/000289231
Dopper EG et al (2011) Symmetrical corticobasal syndrome caused by a novel C.314dup progranulin mutation. J Mol Neurosci 45:354–358. https://doi.org/10.1007/s12031-011-9626-z
Fagan AM et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med 1:371–380. https://doi.org/10.1002/emmm.200900048
Fenoglio C et al (2009) Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer’s disease. J Alzheimers Dis 18:603–612. https://doi.org/10.3233/JAD-2009-1170
Finch N et al (2009) Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain J Neurol 132:583–591. https://doi.org/10.1093/brain/awn352
Galimberti D et al. (2012) Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. PLoS One 7:e32164
Galimberti D et al (2014) Progranulin gene variability influences the risk for bipolar I disorder, but not bipolar II disorder. Bipolar Disord 16:769–772. https://doi.org/10.1111/bdi.12180
Gass J et al (2006) Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 15:2988–3001. https://doi.org/10.1093/hmg/ddl241
Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G (2008) Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71:1235–1239. https://doi.org/10.1212/01.wnl.0000325058.10218.fc
Gliebus G, Rosso A, Lippa CF (2009) Progranulin and beta-amyloid distribution: a case report of the brain from preclinical PS-1 mutation carrier. Am J Alzheimers Dis Other Demen 24:456–460. https://doi.org/10.1177/1533317509346209
Guerreiro RJ et al (2008) Novel progranulin mutation: screening for PGRN mutations in a Portuguese series of FTD/CBS cases. Move Disord 23:1269–1273. https://doi.org/10.1002/mds.22078
Guerreiro RJ, Washecka N, Hardy J, Singleton A (2010) A thorough assessment of benign genetic variability in GRN and MAPT. Hum Mutat 31:E1126–E1140. https://doi.org/10.1002/humu.21152
Hampel H et al (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61:95–102. https://doi.org/10.1001/archpsyc.61.1.95
He Z, Ong CH, Halper J, Bateman A (2003) Progranulin is a mediator of the wound response. Nat Med 9:225–229. https://doi.org/10.1038/nm816
Hosokawa M et al (2015) Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice. J Neuropathol Exp Neurol 74:158–165. https://doi.org/10.1097/NEN.0000000000000158
Hosokawa M et al (2017) Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation. Sci Rep 7:1513. https://doi.org/10.1038/s41598-017-01587-6
Hosokawa M, Tanaka Y, Arai T, Kondo H, Akiyama H, Hasegawa M (2018) Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer’s disease model mice. Exp Anim 67:63–70. https://doi.org/10.1538/expanim.17-0060
Jasinska-Myga B et al (2009) GRN 3′UTR+78 C>T is not associated with risk for Parkinson’s disease. Eur J Neurol 16:909–911. https://doi.org/10.1111/j.1468-1331.2009.02621.x
Jian J et al (2016a) Progranulin recruits HSP70 to beta-glucocerebrosidase and is therapeutic against Gaucher disease. EBioMedicine 13:212–224. https://doi.org/10.1016/j.ebiom.2016.10.010
Jian J et al (2016b) Association between progranulin and Gaucher disease. EBioMedicine 11:127–137. https://doi.org/10.1016/j.ebiom.2016.08.004
Kelley BJ et al (2009) Prominent phenotypic variability associated with mutations in progranulin. Neurobiol Aging 30:739–751. https://doi.org/10.1016/j.neurobiolaging.2007.08.022
Kelley BJ et al (2010) Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch Neurol 67:171–177. https://doi.org/10.1001/archneurol.2010.113
Kittel-Schneider S et al (2014) Further evidence for plasma progranulin as a biomarker in bipolar disorder. J Affect Disord 157:87–91. https://doi.org/10.1016/j.jad.2014.01.006
Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081. https://doi.org/10.1038/nprot.2009.86
Le Ber I et al (2008) Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain J Neurol 131:732–746. https://doi.org/10.1093/brain/awn012
Lee MJ, Chen TF, Cheng TW, Chiu MJ (2011) rs5848 variant of progranulin gene is a risk of Alzheimer’s disease in the Taiwanese population. Neurodegener Dis 8:216–220. https://doi.org/10.1159/000322538
Leverenz JB et al (2007) A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain J Neurol 130:1360–1374. https://doi.org/10.1093/brain/awm069
Lui H et al (2016) Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 165:921–935. https://doi.org/10.1016/j.cell.2016.04.001
Masellis M et al (2006) Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain J Neurol 129:3115–3123. https://doi.org/10.1093/brain/awl276
Mateo I et al (2013) Reduced serum progranulin level might be associated with Parkinson’s disease risk. Eur J Neurol 20:1571–1573. https://doi.org/10.1111/ene.12090
Minami SS et al (2014) Progranulin protects against amyloid beta deposition and toxicity in Alzheimer’s disease mouse models. Nat Med 20:1157–1164. https://doi.org/10.1038/nm.3672
Mukherjee O et al (2006) HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol 60:314–322. https://doi.org/10.1002/ana.20963
Ong CH, Bateman A (2003) Progranulin (granulin-epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histol Histopathol 18:1275–1288. https://doi.org/10.14670/HH-18.1275
Pereson S et al (2009) Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J Pathol 219:173–181. https://doi.org/10.1002/path.2580
Piaceri I et al (2014) Association of the variant Cys139Arg at GRN gene to the clinical spectrum of frontotemporal lobar degeneration. J Alzheimers Dis 40:679–685. https://doi.org/10.3233/JAD-132126
Piaceri I et al (2018) Novel GRN mutations in Alzheimer’s disease and frontotemporal lobar degeneration. J Alzheimers Dis 62:1683–1689. https://doi.org/10.3233/JAD-170989
Pickford F et al (2011) Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am J Pathol 178:284–295. https://doi.org/10.1016/j.ajpath.2010.11.002
Probst A, Taylor KI, Tolnay M (2007) Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol 114:335–345. https://doi.org/10.1007/s00401-007-0262-1
Rademakers R et al (2007) Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol 6:857–868. https://doi.org/10.1016/S1474-4422(07)70221-1
Redaelli V et al (2018) Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (TAR DNA-binding protein 43 inclusions) in missense progranulin mutation Cys139Arg. Brain Pathol 28:72–76. https://doi.org/10.1111/bpa.12480
Rollinson S et al (2011) No association of PGRN 3′UTR rs5848 in frontotemporal lobar degeneration. Neurobiol Aging 32:754–755. https://doi.org/10.1016/j.neurobiolaging.2009.04.009
Rosen EY et al (2011) Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron 71:1030–1042. https://doi.org/10.1016/j.neuron.2011.07.021
Rovelet-Lecrux A et al (2008) Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiol Dis 31:41–45. https://doi.org/10.1016/j.nbd.2008.03.004
Schymick JC et al (2007) Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry 78:754–756. https://doi.org/10.1136/jnnp.2006.109553
Sieben A et al (2018) Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. Alzheimers Res Ther 10:7. https://doi.org/10.1186/s13195-017-0334-y
Simon-Sanchez J, Seelaar H, Bochdanovits Z, Deeg DJ, van Swieten JC, Heutink P (2009) Variation at GRN 3′-UTR rs5848 is not associated with a risk of frontotemporal lobar degeneration in Dutch population. PLoS One 4:e7494. https://doi.org/10.1371/journal.pone.0007494
Sleegers K et al (2008) Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology 71:253–259. https://doi.org/10.1212/01.wnl.0000289191.54852.75
Spina S, Murrell JR, Huey ED, Wassermann EM, Pietrini P, Grafman J, Ghetti B (2007) Corticobasal syndrome associated with the A9D progranulin mutation. J Neuropathol Exp Neurol 66:892–900. https://doi.org/10.1097/nen.0b013e3181567873
Sunderland T et al (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289:2094–2103. https://doi.org/10.1001/jama.289.16.2094
Takahashi H et al (2017) Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathol 133:785–807. https://doi.org/10.1007/s00401-017-1668-z
Tanaka Y, Matsuwaki T, Yamanouchi K, Nishihara M (2013) Exacerbated inflammatory responses related to activated microglia after traumatic brain injury in progranulin-deficient mice. Neuroscience 231:49–60. https://doi.org/10.1016/j.neuroscience.2012.11.032
Tanaka Y et al (2017) Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum Mol Genet 26:969–988. https://doi.org/10.1093/hmg/ddx011
Van Damme P et al (2008) Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181:37–41. https://doi.org/10.1083/jcb.200712039
Wang J et al (2010) Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J Neurochem 112:1305–1315. https://doi.org/10.1111/j.1471-4159.2009.06546.x
Yin F et al (2010) Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med 207:117–128. https://doi.org/10.1084/jem.20091568
Zarow C, Sitzer TE, Chui HC (2008) Understanding hippocampal sclerosis in the elderly: epidemiology, characterization, and diagnostic issues. Curr Neurol Neurosci Rep 8:363–370
Zhu J et al (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111:867–878
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Hosokawa, M. (2019). PGRN and Neurodegenerative Diseases Other Than FTLD. In: Hara, H., Hosokawa, M., Nakamura, S., Shimohata, T., Nishihara, M. (eds) Progranulin and Central Nervous System Disorders. Springer, Singapore. https://doi.org/10.1007/978-981-13-6186-9_4
Download citation
DOI: https://doi.org/10.1007/978-981-13-6186-9_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-6185-2
Online ISBN: 978-981-13-6186-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)